L
L. Radosevic-Jelic
Publications - 10
Citations - 3820
L. Radosevic-Jelic is an academic researcher. The author has contributed to research in topics: Radiation therapy & Cancer. The author has an hindex of 9, co-authored 10 publications receiving 3544 citations.
Papers
More filters
Journal ArticleDOI
Chemotherapy with preoperative radiotherapy in rectal cancer
Jean-François Bosset,Laurence Collette,Gilles Calais,Laurent Mineur,Philippe Maingon,L. Radosevic-Jelic,Alain Daban,Etienne Bardet,Alexander Beny,Jean-Claude Ollier +9 more
TL;DR: In patients with rectal cancer who receive preoperative radiotherapy, adding fluorouracil-based chemotherapy preoperatively or postoperatively has no significant effect on survival.
Journal ArticleDOI
Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results—EORTC 22921
Jean-François Bosset,Gilles Calais,Laurent Mineur,Philippe Maingon,L. Radosevic-Jelic,Alain Daban,Etienne Bardet,Alexander Beny,Antoine Briffaux,Laurence Collette +9 more
TL;DR: In patients with rectal cancer, preliminary results of EORTC Trial 22921 indicate that the addition of CT to preop RT induces down-sizing, downstaging, and significant changes in histologic characteristics.
Journal ArticleDOI
Patients With Curative Resection of cT3-4 Rectal Cancer After Preoperative Radiotherapy or Radiochemotherapy: Does Anybody Benefit From Adjuvant Fluorouracil-Based Chemotherapy? A Trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group
Laurence Collette,Jean-François Bosset,Marcel den Dulk,Laurent Mineur,Philippe Maingon,L. Radosevic-Jelic,Marianne Pierart,Gilles Calais +7 more
TL;DR: Exploratory analyses suggest that only good-prognosis patients (ypT0-2) benefit from adjuvant CT, and suggests that the same prognostic factors may drive both tumor sensitivity for the primary treatment and long-term clinical benefit from further adjUvant CT.
Journal ArticleDOI
Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group.
J.F. Bosset,Gilles Calais,Alain Daban,C. Berger,L. Radosevic-Jelic,P. Maingon,Etienne Bardet,Marianne Pierart,A. Briffaux +8 more
TL;DR: At the doses recommended in the protocol, the addition of 5-FU-LV to preoperative XRT slightly increased the amount of acute toxicity, however, the compliance with the radiation protocol or the feasibility of surgery did not decrease.
Journal ArticleDOI
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
F. Bonnetain,J.-F. Bosset,Jean-Pierre Gerard,Gilles Calais,T. Conroy,Laurent Mineur,O. Bouche,P. Maingon,O. Chapet,L. Radosevic-Jelic,N. Methy,Laurence Collette +11 more
TL;DR: Preoperative CRT does not prolong OS or PFS and pCR or LC do not qualify as surrogate for PFS or OS while PFS is surrogate.